<h3>Purpose</h3> There has been a remarkable increase in the number of pediatric ventricular assist devices (VAD) implanted over the past decade. Asian pediatric heart centers had not participated in the multicenter registries of the Western countries. This article aimed to report the outcomes of pediatric VAD in our institution from the Asia-Pacific region. <h3>Methods</h3> Prospectively registered VAD database was reviewed. Data of patients younger than 18 years at the time of VAD implantation were retrieved. The study group enrolled all pediatric patients who underwent VAD implantation between January 2008 and July 2021. <h3>Results</h3> There were 33 patients with diagnosis of acute fulminant myocarditis (N = 9), congenital heart disease (N = 5), dilated cardiomyopathy (N = 16), restrictive cardiomyopathy (N = 2) and chronic rejection with graft failure (N = 1). Paracorporeal continuous-flow pump was the most frequently implanted (N = 27). Most of the devices were implanted in patients with INTERMACS profile 1 (N = 24). The median duration on VAD was 22 days (range 2-254 days). The proportion of patients attaining positive outcomes (alive on device, bridge to transplantation or recovery) was 72.7% at 1 month, 67.7% at 3 months, and 67.7% at 6 months. Most of the deaths on device occurred within the first month post-implant (N = 9), with neurological complications being the most frequent cause of death. All recovered cases were successfully weaned off the device within the first month of implantation. <h3>Conclusion</h3> We demonstrated a favorable outcome in pediatric patients supported with VAD, predominantly the paracorporeal continuous-flow pump, at our institution from the Asia-Pacific region.